NTLA - Intellia Therapeutics, Inc.
After hours:
| Previous Close | 39.22 |
| Open | 39.04 |
| Bid | 39.05 x 900 |
| Ask | 39.20 x 800 |
| Day's Range | 38.01 - 39.42 |
| 52 Week Range | 32.44 - 76.45 |
| Volume | |
| Avg. Volume | 1,097,966 |
| Market Cap | 3.436B |
| Beta (5Y Monthly) | 1.85 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Motley Fool
Cathie Wood Is Loading Up on These 3 Stocks Down 70% or More. Should You?
Cathie Wood looks for stocks that are leading innovators. But the stocks that fit that mold aren't always leaders when it comes to delivering huge returns over the short term. On the contrary, quite a few of the stocks in Wood's Ark Invest portfolios have been big losers.
- Zacks
Are You Looking for a Top Momentum Pick? Why Intellia Therapeutics, Inc. (NTLA) is a Great Choice
Does Intellia Therapeutics, Inc. (NTLA) have what it takes to be a top stock pick for momentum investors? Let's find out.
- Zacks
Wall Street Analysts Think Intellia Therapeutics, Inc. (NTLA) Could Surge 115.12%: Read This Before Placing a Bet
The consensus price target hints at an 115.1% upside potential for Intellia Therapeutics, Inc. (NTLA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
- Zacks
Intellia (NTLA) Beats on Q1 Earnings, Gives Pipeline Update
Intellia's (NTLA) first-quarter earnings beat estimates. The company provides updates on its gene-editing pipeline.
- Zacks
Intellia Therapeutics, Inc. (NTLA) Reports Q1 Loss, Lags Revenue Estimates
Intellia Therapeutics, Inc. (NTLA) delivered earnings and revenue surprises of 17.02% and 4.82%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
- Motley Fool
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
The popular growth investor has stumbled after a hot start to 2023, but Wood keeps adding to some of her favorite positions.
- Motley Fool
2 Monster Growth Stocks That Can Double in Value, According to Wall Street
These stocks have some promising growth opportunities, but they also come with a fair amount of risk.
- Simply Wall St.
Investors push Intellia Therapeutics (NASDAQ:NTLA) 3.5% lower this week, company's increasing losses might be to blame
The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But when you pick a company...
- Zacks
Intellia's (NTLA) HAE Therapy Granted RMAT by the FDA
Intellia Therapeutics' (NTLA) in vivo CRISPR-based investigational therapy, NTLA-2002, gets Regenerative Medicine Advanced Therapy designation for the treatment of hereditary angioedema.
- Motley Fool
3 Beaten-Down Stocks That Could Soar This Year
Here's why they picked CRISPR Therapeutics (NASDAQ: CRSP), Exelixis (NASDAQ: EXEL), and Intellia Therapeutics (NASDAQ: NTLA). Prosper Junior Bakiny (CRISPR Therapeutics): Unprofitable clinical-stage biotech companies got hammered last year. Gene-editing specialist CRISPR Therapeutics fits that description to a T, so it got dragged down along with the broader market.
- Motley Fool
Got $2,000? 3 Growth Stocks to Buy That Could Double Your Money
There are no guarantees that any stock will generate huge returns. But the odds look pretty good for these three growth stocks.
- Motley Fool
2 Cathie Wood Stocks That Have Tripled Since the 2020 Market Crash
Cathie Wood's favorite stocks have been synonymous with growth, and although many of them have been struggling of late, there are a couple that have tripled in value in the past three years: Tesla (NASDAQ: TSLA) and Intellia Therapeutics (NASDAQ: NTLA). Since March 2020, shares of Tesla have soared 334%. Tesla also ended up joining the S&P 500 late in 2020 in a sign of its growing stability.
- Motley Fool
Why Intellia Therapeutics Stock Jumped This Week
Shares of the gene-editing pioneer Intellia Therapeutics (NASDAQ: NTLA) rose by 17.5% through the first three and a half days of trading this week, according to data provided by S&P Global Market Intelligence. There are currently eight medications approved by the FDA to prevent and/or treat HAE attacks. NTLA-2002, however, could be the first genetic medicine for this indication (depending on its ongoing clinical trials).
- Zacks
Intellia's (NTLA) Q4 Loss Matches Estimates, Revenues Up Y/Y
Intellia Therapeutics (NTLA) reports loss for fourth-quarter 2022, in line with estimates.
- Zacks
Intellia Therapeutics, Inc. (NTLA) Reports Q4 Loss, Tops Revenue Estimates
Intellia Therapeutics, Inc. (NTLA) delivered earnings and revenue surprises of 0% and 11.06%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- Zacks
Is Intellia Therapeutics (NTLA) Stock Outpacing Its Medical Peers This Year?
Here is how Intellia Therapeutics, Inc. (NTLA) and Centogene N.V. (CNTG) have performed compared to their sector so far this year.
- Motley Fool
Better Buy: Beam Therapeutics or Intellia Therapeutics?
Gene-editing biotech companies are showing the potential to cure diseases. The Food and Drug Administration (FDA) could approve the first CRISPR gene-editing therapy this year -- exa-cel, developed by CRISPR Therapeutics and Vertex Pharmaceuticals -- to treat severe sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TBT), a blood disorder associated with anemia. Two others to watch for with solid long-term prospects are Beam Therapeutics (NASDAQ: BEAM) and Intellia Therapeutics (NASDAQ: NTLA).
- Zacks
Earnings Preview: Revance Therapeutics, Inc. (RVNC) Q4 Earnings Expected to Decline
Revance Therapeutics, Inc. (RVNC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks
Intellia Therapeutics, Inc. (NTLA) Expected to Beat Earnings Estimates: Should You Buy?
Intellia Therapeutics, Inc. (NTLA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Motley Fool
3 Deeply Undervalued Stocks That Could Double Your Money
Growth stocks had an exceptionally rough 2022. Supply chain woes, sky-high inflation, rising interest rates, and the conflict in Ukraine all conspired last year to spur a major correction across the growth equity landscape. In turn, Wall Street analysts think there are some tremendous bargains within this space right now.
- Motley Fool
3 Cathie Wood Stocks That Could More Than Double in 12 Months, According to Wall Street
Analysts are bearish, for example, on the three stocks that have helped the most in Wood's Ark Innovation ETF (NYSEMKT: ARKK) trouncing the market so far in 2023. Here are three Cathie Wood stocks that could more than double in 12 months, according to Wall Street. Wood owns shares of Intellia Therapeutics (NASDAQ: NTLA) in two of her ETFs -- the flagship Ark Innovation ETF and the Ark Genomic Revolution ETF (NYSEMKT: ARKG).
- Zacks
Wall Street Analysts Believe Intellia Therapeutics, Inc. (NTLA) Could Rally 145.32%: Here's is How to Trade
The mean of analysts' price targets for Intellia Therapeutics, Inc. (NTLA) points to a 145.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
- Motley Fool
3 Cathie Wood Stocks Wall Street Thinks Can Soar 60% to 129%
Cathie Wood is roaring back. Her flagship ARK Innovation ETF (NYSEMKT: ARKK) plunged 67% last year. But so far in 2023, the exchange-traded fund is up nearly 40%. This impressive performance could be just the warm-up.
- Zacks
4 Biotech Stocks Set to Outpace Q4 Earnings Estimates
Let us look at some biotech stocks, ALLO, EDIT, NTLA and SGEN that are poised to beat on fourth-quarter earnings.
- Zacks
Does Intellia Therapeutics, Inc. (NTLA) Have the Potential to Rally 185.4% as Wall Street Analysts Expect?
The consensus price target hints at an 185.4% upside potential for Intellia Therapeutics, Inc. (NTLA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
